

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Biglycan in direct ELISAs and Western blots.
Source	Monoclonal Mouse IgG ₁ Clone # 303203
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Biglycan Asp38-Lys368 Accession # P21810
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Biglycan, also known as PG I, is a secreted chondroitin/dermatan sulfate proteoglycan in the small leucine-rich proteoglycan (SLRP) family. SLRP family members are characterized by N-terminal and C-terminal cysteine-rich regions that flank a central region containing 10 - 12 tandem leucine-rich repeats (LRRs). Biglycan function is important in the development and maintenance of many tissues (1, 2). The human Biglycan cDNA encodes a 368 amino acid (aa) precursor with a 19 aa signal sequence and a 18 aa propeptide that is cleaved by BMP-1 (3). Mature Biglycan contains N-linked glycosylation in addition to two glycosaminoglycan (GAG) chains (4). The 45 kDa core protein is approximately one third the molecular weight of the fully glycanated form and can assemble into noncovalently-associated dimers (5). Human Biglycan shares 97% aa sequence identity with bovine, mouse, and rat Biglycan and 57% aa sequence identity with human Decorin. Biglycan binds several matrix proteins, including fibrillar collagens, Matrilin-1, and β IG-H3 (6 - 8). Its multiple LRRs, N-linked glycosylation, and GAG chains mediate distinct interactions that enable extensive crosslinking and stabilization of the collagen matrix (6 - 8). Mature Biglycan can be further cleaved by proteases, resulting in non-glycanated fragments (9). In osteoarthritis, MMP-13-induced breakdown of Biglycan likely interferes with collagen crosslinking and contributes to cartilage degradation (10). Biglycan also binds and modulates the activity of a variety of non-matrix proteins, including BMP-4, C1q, collectins, TGF- β , TNF- α , and WISP-1 (11, 12). Biglycan functions as a proinflammatory mediator by binding TLR2 and TLR4 on macrophages and inducing TNF- α and MIP-2 production (13). Biglycan knockout mice have compromised inflammatory responses and are resistant to LPS-induced septic shock (13). Biglycan binds HDL/Apolipoprotein E complexes in atherosclerotic plaques and also binds SR-A, blocking the uptake and degradation of LDL (14, 15).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.